MX2019007795A - Moleculas de union a antigeno biespecificas que comprenden el clon 20h4.9 anti-4-1bb. - Google Patents

Moleculas de union a antigeno biespecificas que comprenden el clon 20h4.9 anti-4-1bb.

Info

Publication number
MX2019007795A
MX2019007795A MX2019007795A MX2019007795A MX2019007795A MX 2019007795 A MX2019007795 A MX 2019007795A MX 2019007795 A MX2019007795 A MX 2019007795A MX 2019007795 A MX2019007795 A MX 2019007795A MX 2019007795 A MX2019007795 A MX 2019007795A
Authority
MX
Mexico
Prior art keywords
antigen binding
clone
bispecific antigen
binding molecules
molecules
Prior art date
Application number
MX2019007795A
Other languages
English (en)
Inventor
Ferrara Koller Claudia
Umaña Pablo
Claus Christina
Klein Christian
Xu Wei
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61024728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019007795(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019007795A publication Critical patent/MX2019007795A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G5/00—Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators
    • G09G5/36—Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators characterised by the display of a graphic pattern, e.g. using an all-points-addressable [APA] memory
    • G09G5/37—Details of the operation on graphic patterns
    • G09G5/377—Details of the operation on graphic patterns for mixing or overlaying two or more graphic patterns
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N9/00—Details of colour television systems
    • H04N9/12—Picture reproducers
    • H04N9/31—Projection devices for colour picture display, e.g. using electronic spatial light modulators [ESLM]
    • H04N9/3102—Projection devices for colour picture display, e.g. using electronic spatial light modulators [ESLM] using two-dimensional electronic spatial light modulators
    • H04N9/312—Driving therefor
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N9/00—Details of colour television systems
    • H04N9/12—Picture reproducers
    • H04N9/31—Projection devices for colour picture display, e.g. using electronic spatial light modulators [ESLM]
    • H04N9/3179—Video signal processing therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2320/00—Control of display operating conditions
    • G09G2320/02—Improving the quality of display appearance
    • G09G2320/0257—Reduction of after-image effects
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2320/00—Control of display operating conditions
    • G09G2320/04—Maintaining the quality of display appearance
    • G09G2320/043—Preventing or counteracting the effects of ageing
    • G09G2320/046—Dealing with screen burn-in prevention or compensation of the effects thereof
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2320/00—Control of display operating conditions
    • G09G2320/04—Maintaining the quality of display appearance
    • G09G2320/043—Preventing or counteracting the effects of ageing
    • G09G2320/048—Preventing or counteracting the effects of ageing using evaluation of the usage time
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2320/00—Control of display operating conditions
    • G09G2320/06—Adjustment of display parameters
    • G09G2320/0606—Manual adjustment
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2354/00—Aspects of interface with display user

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Multimedia (AREA)
  • Signal Processing (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a nuevas moléculas de unión a antígeno biespecíficas, que comprende al menos un dominio de unión a antígeno capaz de unirse de manera específica a 4-1BB, al menos un resto capaz de unirse de manera específica a un antígeno de célula diana y un dominio Fc formado por una primera y un segunda subunidad capaces de asociarse de manera estable y a métodos para producir estas moléculas y a métodos para usar las mismas.
MX2019007795A 2017-01-03 2018-01-02 Moleculas de union a antigeno biespecificas que comprenden el clon 20h4.9 anti-4-1bb. MX2019007795A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17150150 2017-01-03
EP17164224 2017-03-31
PCT/EP2018/050024 WO2018127473A1 (en) 2017-01-03 2018-01-02 Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9

Publications (1)

Publication Number Publication Date
MX2019007795A true MX2019007795A (es) 2019-08-16

Family

ID=61024728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007795A MX2019007795A (es) 2017-01-03 2018-01-02 Moleculas de union a antigeno biespecificas que comprenden el clon 20h4.9 anti-4-1bb.

Country Status (19)

Country Link
US (2) US11447558B2 (es)
EP (1) EP3565843A1 (es)
JP (1) JP7122311B2 (es)
KR (1) KR20190099527A (es)
CN (1) CN110461873B (es)
AU (1) AU2018206138A1 (es)
BR (1) BR112019013189A2 (es)
CA (1) CA3047070A1 (es)
CL (1) CL2019001828A1 (es)
CO (1) CO2019007046A2 (es)
CR (1) CR20190309A (es)
IL (1) IL267607A (es)
MA (1) MA47200A (es)
MX (1) MX2019007795A (es)
PE (1) PE20191546A1 (es)
PH (1) PH12019501440A1 (es)
RU (1) RU2019123613A (es)
TW (1) TW201829469A (es)
WO (1) WO2018127473A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049982T2 (hu) 2014-11-14 2020-11-30 Hoffmann La Roche TNF-családba tartozó ligandum-trimert tartalmazó antigénkötõ molekulák
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
PL3559034T3 (pl) 2016-12-20 2021-04-19 F. Hoffmann-La Roche Ag Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
CN110573528B (zh) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
CA3058477A1 (en) 2017-04-11 2018-10-18 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
US20210324108A1 (en) * 2017-11-01 2021-10-21 Hoffmann-La Roche Inc. Bispecific 2+1 contorsbodies
CN112424228A (zh) * 2018-07-04 2021-02-26 豪夫迈·罗氏有限公司 新型双特异性激动性4-1bb抗原结合分子
TW202035451A (zh) * 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
CN112654641A (zh) * 2018-10-01 2021-04-13 豪夫迈·罗氏有限公司 具有与cd40的三价结合的双特异性抗原结合分子
JP7221379B2 (ja) * 2018-10-01 2023-02-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｆａｐクローン２１２を含む二重特異性抗原結合分子
WO2020127618A1 (en) * 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted agonistic cd28 antigen binding molecules
MX2021006428A (es) * 2019-08-12 2021-11-17 I Mab Biopharma Us Ltd Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso.
WO2021041300A2 (en) * 2019-08-23 2021-03-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
CR20220586A (es) * 2020-05-19 2023-01-09 Boehringer Ingelheim Int Moléculas de fijación para el tratamiento de cáncer
CN115916825A (zh) 2020-06-19 2023-04-04 豪夫迈·罗氏有限公司 与cd3和cd19结合的抗体
TW202246351A (zh) * 2021-02-08 2022-12-01 美商恩格姆生物製藥公司 Htra1結合劑及其使用方法
WO2022243261A1 (en) * 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
TW202330600A (zh) * 2021-08-24 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Fap/cd40 結合分子及其醫藥用途
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024042105A1 (en) * 2022-08-26 2024-02-29 Merck Patent Gmbh Cancer treatment comprising an anti-msln/cd137 antibody and a chemotherapeutic
WO2024042104A1 (en) * 2022-08-26 2024-02-29 Merck Patent Gmbh Combination cancer treatment comprising an anti-msln/cd137 antibody and pd-1/pd-l1 inhibitor

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE4106389A1 (de) 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
BRPI0316779B1 (pt) 2002-12-16 2020-04-28 Genentech Inc anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JP4871126B2 (ja) 2003-07-04 2012-02-08 アフィボディ・アーベー Ｈｅｒ２に対する結合親和性を有するポリペプチド
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
RS58420B1 (sr) 2003-11-05 2019-04-30 Roche Glycart Ag Cd20 antitela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
SG149004A1 (en) 2003-12-05 2009-01-29 Bristol Myers Squibb Co Inhibitors of type 2 vascular endothelial growth factor receptors
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PL1976880T3 (pl) 2005-12-21 2017-01-31 Amgen Research (Munich) Gmbh Kompozycje farmaceutyczne odporne na rozpuszczalny cea
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2012002006A1 (ja) 2010-06-29 2012-01-05 コニカミノルタエムジー株式会社 超音波診断装置及びプログラム
SI2603530T1 (en) 2010-08-13 2018-02-28 Roche Glycart Ag Anti-FAP antibodies and methods of use
MX354359B (es) * 2011-03-29 2018-02-28 Roche Glycart Ag Variantes de fragmento cristalizable (fc) de los anticuerpos.
US9718893B2 (en) * 2011-12-19 2017-08-01 Synimmune Gmbh Bispecific antibody molecule
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
NZ724710A (en) 2014-04-07 2024-02-23 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
SI3186283T1 (sl) 2014-08-29 2020-04-30 F. Hoffmann-La Roche Ag Kombinirana terapija z imunocitokini različice IL-2, usmerjenimi proti tumorju in protitelesi proti humanemu PD-L1
HUE049982T2 (hu) 2014-11-14 2020-11-30 Hoffmann La Roche TNF-családba tartozó ligandum-trimert tartalmazó antigénkötõ molekulák
JP2018503399A (ja) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 多特異性免疫調節抗原結合構築物
JP6996979B2 (ja) 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
CN107636014B (zh) * 2015-05-04 2021-12-07 皮里斯制药有限公司 抗癌融合多肽
HUE061108T2 (hu) * 2015-05-18 2023-05-28 Pieris Pharmaceuticals Gmbh Rákellenes fúziós polipeptid
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3356403A2 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
EP3356407B1 (en) 2015-10-02 2021-11-03 F. Hoffmann-La Roche AG Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
CR20180175A (es) 2015-10-02 2018-05-03 Hoffmann La Roche Anticuerpos anti-cd19 humano con alta afinidad
MX2018004157A (es) 2015-10-07 2019-04-01 F Hoffmann ­La Roche Ag Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador.
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
EP3455254B1 (en) 2016-05-11 2021-07-07 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
EP3554542A1 (en) 2016-12-19 2019-10-23 H. Hoffnabb-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
PL3559034T3 (pl) 2016-12-20 2021-04-19 F. Hoffmann-La Roche Ag Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
CN110573528B (zh) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
EP3601346A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
MA49039A (fr) 2017-04-04 2020-02-12 Hoffmann La Roche Nouvelles molécules bispécifiques de liaison à l'antigène capables de se lier spécifiquement à cd40 et à fap
EP3703746A1 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Novel tnf family ligand trimer-containing antigen binding molecules
AU2018359506A1 (en) 2017-11-01 2020-04-23 F. Hoffmann-La Roche Ag Combination therapy with targeted OX40 agonists
US20210324108A1 (en) 2017-11-01 2021-10-21 Hoffmann-La Roche Inc. Bispecific 2+1 contorsbodies
CN111655731A (zh) 2018-03-13 2020-09-11 豪夫迈·罗氏有限公司 用靶向性4-1bb(cd137)激动剂的组合疗法
AU2019236372B2 (en) 2018-03-13 2024-06-20 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 BB agonists with anti-CD20 antibodies
PE20210652A1 (es) 2018-04-13 2021-03-26 Hoffmann La Roche Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
CN112424228A (zh) 2018-07-04 2021-02-26 豪夫迈·罗氏有限公司 新型双特异性激动性4-1bb抗原结合分子
CN112654641A (zh) 2018-10-01 2021-04-13 豪夫迈·罗氏有限公司 具有与cd40的三价结合的双特异性抗原结合分子
JP7221379B2 (ja) 2018-10-01 2023-02-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｆａｐクローン２１２を含む二重特異性抗原結合分子
WO2020208049A1 (en) 2019-04-12 2020-10-15 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising lipocalin muteins
TW202115124A (zh) 2019-06-26 2021-04-16 瑞士商赫孚孟拉羅股份公司 結合至cea之新穎抗原結合分子
EP4087866A1 (en) 2020-01-09 2022-11-16 F. Hoffmann-La Roche AG New 4-1bbl trimer-containing antigen binding molecules
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap

Also Published As

Publication number Publication date
PE20191546A1 (es) 2019-10-24
US11447558B2 (en) 2022-09-20
WO2018127473A1 (en) 2018-07-12
IL267607A (en) 2019-08-29
CO2019007046A2 (es) 2019-07-10
MA47200A (fr) 2019-11-13
KR20190099527A (ko) 2019-08-27
CN110461873A (zh) 2019-11-15
BR112019013189A2 (pt) 2019-12-10
CL2019001828A1 (es) 2019-10-18
PH12019501440A1 (en) 2020-02-10
AU2018206138A1 (en) 2019-07-11
JP7122311B2 (ja) 2022-08-19
CR20190309A (es) 2019-08-21
JP2020504622A (ja) 2020-02-13
US20230045262A1 (en) 2023-02-09
CN110461873B (zh) 2023-05-12
CA3047070A1 (en) 2018-07-12
TW201829469A (zh) 2018-08-16
US20200190206A1 (en) 2020-06-18
RU2019123613A (ru) 2021-02-05
EP3565843A1 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
PH12019501440A1 (en) Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
MX2023006482A (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
PH12018500766A1 (en) Bispecific antibodies with tetravalency for a costimulatory tnf receptor
PH12019502294A1 (en) Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
PH12018500156A1 (en) Antibody constructs for egfrviii and cd3
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
WO2019224718A3 (en) Psma binding agents and uses thereof
PH12018500241A1 (en) Antibody constructs for dll3 and cd3
CR20210326A (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
MX2021008367A (es) Constructos de anticuerpos para cdh19 y cd3.
EP4327885A3 (en) Antibody constructs for msln and cd3
EP4276116A3 (en) Bispecific antibody constructs for cdh3 and cd3
JO3714B1 (ar) تركيبات الجسم المضاد لـ cd70 و cd3
JO3792B1 (ar) تركيبات الجسم المضاد لـ flt3 و cd3
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
WO2018151821A8 (en) ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
MX2017001403A (es) Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
EP3853257A4 (en) Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof